JP2015509948A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509948A5
JP2015509948A5 JP2014558901A JP2014558901A JP2015509948A5 JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5 JP 2014558901 A JP2014558901 A JP 2014558901A JP 2014558901 A JP2014558901 A JP 2014558901A JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014558901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509948A (ja
JP6401060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/027476 external-priority patent/WO2013126810A1/en
Publication of JP2015509948A publication Critical patent/JP2015509948A/ja
Publication of JP2015509948A5 publication Critical patent/JP2015509948A5/ja
Application granted granted Critical
Publication of JP6401060B2 publication Critical patent/JP6401060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014558901A 2012-02-24 2013-02-22 抗sez6抗体及び使用方法 Expired - Fee Related JP6401060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603203P 2012-02-24 2012-02-24
US61/603,203 2012-02-24
PCT/US2013/027476 WO2013126810A1 (en) 2012-02-24 2013-02-22 Anti sez6 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018052506A Division JP2018127469A (ja) 2012-02-24 2018-03-20 抗sez6抗体及び使用方法

Publications (3)

Publication Number Publication Date
JP2015509948A JP2015509948A (ja) 2015-04-02
JP2015509948A5 true JP2015509948A5 (https=) 2016-04-14
JP6401060B2 JP6401060B2 (ja) 2018-10-03

Family

ID=47790548

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014558901A Expired - Fee Related JP6401060B2 (ja) 2012-02-24 2013-02-22 抗sez6抗体及び使用方法
JP2018052506A Pending JP2018127469A (ja) 2012-02-24 2018-03-20 抗sez6抗体及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018052506A Pending JP2018127469A (ja) 2012-02-24 2018-03-20 抗sez6抗体及び使用方法

Country Status (20)

Country Link
US (3) US9676850B2 (https=)
EP (2) EP2817339B1 (https=)
JP (2) JP6401060B2 (https=)
KR (1) KR102099073B1 (https=)
CN (2) CN108383909B (https=)
AU (3) AU2013203506B2 (https=)
CA (1) CA2865415C (https=)
CL (2) CL2014002237A1 (https=)
CO (1) CO7151485A2 (https=)
ES (1) ES2741936T3 (https=)
IL (1) IL234208B (https=)
MX (2) MX373141B (https=)
MY (1) MY178120A (https=)
NZ (1) NZ631197A (https=)
PE (1) PE20150091A1 (https=)
PH (2) PH12020500604A1 (https=)
RU (1) RU2691698C2 (https=)
SG (2) SG11201405130UA (https=)
WO (1) WO2013126810A1 (https=)
ZA (1) ZA201406967B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865415C (en) * 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
US11531028B2 (en) * 2013-05-10 2022-12-20 Nordic Bioscience A/S Collagen type X alpha-1 assay
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
SG11201604503XA (en) * 2013-12-03 2016-07-28 Agency Science Tech & Res Cytotoxic antibody
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
EP3101131B1 (en) * 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
US9631024B2 (en) 2014-06-23 2017-04-25 Bionomics, Inc. Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法
US11294038B2 (en) 2015-10-06 2022-04-05 Pioneer Corporation Light control device, light control method and program
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
US11214612B2 (en) 2016-10-14 2022-01-04 Nima Acquisition, Llc Anti-gliadin antibodies, encoding nucleic acids and methods of detecting gliadin
CA3040421A1 (en) * 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
EP3424528A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Biologische bindemoleküle
EP3774898A4 (en) * 2018-04-13 2022-01-26 Dingfu Biotarget Co., Ltd. ANTI-CD27 ANTIBODIES AND USE THEREOF
US20210196834A1 (en) * 2018-05-30 2021-07-01 Abbvie Stemcentrx Llc Anti-sez6 antibody drug conjugates and methods of use
WO2020013644A1 (ko) * 2018-07-11 2020-01-16 고려대학교 산학협력단 Smo 단백질의 특이적 에피토프, 이를 인지하는 항체 및 이를 포함하는 조성물
TW202537643A (zh) 2018-07-31 2025-10-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
CN115991781A (zh) * 2018-08-24 2023-04-21 江苏恒瑞医药股份有限公司 结合人il-4r的抗体、其抗原结合片段及其医药用途
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
CN114106176B (zh) * 2020-09-01 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
US20230287090A1 (en) * 2020-09-02 2023-09-14 The Feinstein Institutes For Medical Research USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
CN113307875B (zh) * 2021-06-10 2022-09-02 福州迈新生物技术开发有限公司 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用
WO2023019174A2 (en) * 2021-08-11 2023-02-16 Apollos Diagnostics, Llc Antibodies to sars-cov-2
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
US20260061065A1 (en) 2022-05-20 2026-03-05 Novartis Ag Antibody drug conjugates
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
WO2024230742A1 (zh) 2023-05-08 2024-11-14 上海翰森生物医药科技有限公司 一种抗体或其抗原结合片段、抗体-药物偶联物及其应用
CN117736331B (zh) * 2024-02-04 2024-05-07 南昌大学第一附属医院 一种特异性结合psma胞外段的单克隆抗体及其应用
WO2025167503A1 (en) * 2024-02-05 2025-08-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-sez6/b7h3 antibodies and uses thereof
CN119409821B (zh) * 2024-10-18 2025-07-29 北京大学第一医院(北京大学第一临床医学院) 一种抗sez6纳米抗体或抗原结合片段与应用
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1290026A2 (en) * 2000-04-28 2003-03-12 Eli Lilly And Company Human sez6 nucleic acids and polypeptides
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
US20030211991A1 (en) 2001-04-17 2003-11-13 Su Eric Wen Human sez6 nucleic acids and polypeptides
CN1343774A (zh) 2001-05-28 2002-04-10 复旦大学 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
DK1633784T3 (da) 2003-05-09 2011-10-24 Diadexus Inc OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
SI2270010T1 (sl) 2004-03-01 2012-05-31 Spirogen Ltd hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
EP2032694A4 (en) 2006-06-06 2010-09-15 Univ Tennessee Res Foundation COMPOSITIONS ENRICHED WITH NEOPLASTIC STEM CELLS AND THESE COMPREHENSIVE METHODS
KR101496433B1 (ko) 2006-06-07 2015-02-26 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 cd-43 및 cea 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
ES2646545T3 (es) 2006-09-07 2017-12-14 Arthur E. Frankel Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン,エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
KR20110108390A (ko) 2009-01-12 2011-10-05 신텔렉트 인코포레이티드 레이저로 매개된 박막 절개 및 세포 군체의 이동
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
SG183542A1 (en) * 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
WO2012012801A2 (en) 2010-07-23 2012-01-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
WO2012019060A1 (en) * 2010-08-05 2012-02-09 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
CA2865415C (en) * 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) * 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物

Similar Documents

Publication Publication Date Title
JP2015509948A5 (https=)
JP2015509947A5 (https=)
JP2018127469A5 (https=)
JP2016538318A5 (https=)
ES2566602T3 (es) Anticuerpos anti-ErbB3
JP2016510002A5 (https=)
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
JP2016536020A5 (https=)
HRP20191169T1 (hr) Konjugati antidll3-protutijelo-pbd i njihove uporabe
JP2017518040A5 (https=)
JP2016531915A5 (https=)
JP2017500028A5 (https=)
JP2017535246A5 (https=)
JP2016512551A5 (https=)
JP2011046732A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
JP2017512765A5 (https=)
JP2021514973A5 (https=)
RU2019118359A (ru) Антитело к cd73 человека
JP2019532056A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2010520290A5 (https=)
RU2016145277A (ru) Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака
JP2014530017A5 (https=)
JP2015503909A5 (https=)